Trial · NCT07343206
Early Norepinephrine Administration and Rapid Dose Adjustment
NCT07343206, Not applicable, Recruiting, Siriraj Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Early Norepinephrine Administration and Rapid Dose Adjustment. Trials, record NCT07343206. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07343206
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Early Norepinephrine Administration and Rapid Dose Adjustment
- NCT number
- NCT07343206
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 600 participants, estimated
- Lead sponsor
- Siriraj Hospital
- Conditions
- Sepsis, Septic Shock
- Interventions
- Early norepinephrine administration and rapid dose adjustment, Control
- First posted
- 2026-01-15
- Last updated
- 2026-04-22
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day survival | From enrollment to 28 days after enrollment | Survival at 28-day after enrollment. Telephone follow-up for patients who are discharged before 28 days. |
| Secondary | Number of participants with shock control achieved | From enrollment to 6 hours after enrollment | Shock control defined as mean arterial pressure greater than 65 mmHg combined with urine output greater than 0.5 milliliters per kilogram per hour OR lactate clearance greater than 10 percent within 6 hours |
| Secondary | Duration of intensive care unit stay | From enrollment to hospital discharge or 90 days (whichever comes first) | Days of intensive care unit stay |
| Secondary | Duration of hospital stay | From enrollment to hospital discharge or 90 days (whichever comes first) | Days of hospital stay |
| Secondary | Duration of mechanical ventilation | From enrollment to hospital discharge or 90 days (whichever comes first) | Days on mechanical ventilation, including endotracheal tube and tracheostomy |
| Secondary | Duration of renal replacement therapy | From enrollment to hospital discharge or 90 days (whichever comes first) | Days requiring renal replacement therapy, including continuous renal replacement therapy, intermittent hemodialysis, and peritoneal dialysis, that is newly initiated during this admission. Maintaining chronic hemodialysis is excluded. |
| Secondary | Duration of vasopressor therapy | From enrollment to hospital discharge or 90 days (whichever comes first) | Days requiring vasopressor therapy |
| Secondary | Time to Achievement of Early Goal-Directed Therapy Targets | From study drug initiation until achievement of all EGDT targets or up to 6 hours | Time in hours to achieve ALL EGDT targets: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/hr, lactate clearance ≥10%, and ScvO₂ ≥70% (when measured) |
| Secondary | Cumulative Fluid Volume Administered | Multiple assessments at: - Before randomization (baseline) - 1 hour after study drug initiation - 6 hours after study drug initiation - 24 hours (Day 1) 48 hours (Day 2) 72 hours (Day 3) after study drug initiation | Total volume in milliliters of intravenous crystalloid and colloid fluids administered during first 24 hours and first 72 hours Time Frame: At 1 hour, 6 hours, 24 hours (Day 1), 48 hours (Day 2), and 72 hours (Day 3) after treatment initiation |
| Secondary | Incidence of Pulmonary Edema | From diagnosis until hospital discharge 90 days or death | New-onset cardiogenic pulmonary edema or non-cardiogenic pulmonary edema |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07343206
GET https://conductscience.org/api/trials/v1/NCT07343206/registered